Health of "millions" threatened by HFC curbs, claims GlaxoWellcome

Pharmaceuticals giant GlaxoWellcome has claimed that controls on HFCs under the Kyoto Protocol on climate change could affect the health of "millions" of patients with respiratory illnesses who use metered dose inhalers (MDIs). Its £2 billion per year inhalers business is built largely around MDIs. But Swedish officials maintain that many patients could use alternative dry powder inhalers (DPIs) which do not contain HFCs.

Sign in to continue

Sign in

Trouble signing in?

Reset password: Click here


Call: 020 8267 8120

Take a 30-day trial

  • Join ENDS Report now and pay nothing for your first 30-days.



Prices on request

  • Full access to for 12 months
  • Clear and accessible guidance on relevant legislation
  • Integration with ENDS Compliance Manager helping you plan ahead and ensure compliance for your organisation
  • Individual or bespoke multi-user packages available

See all benefits

Need to activate your subscription?
Already a subscriber
If you haven't already, activate your subscription here>>
Company Domain Access
If your company or university has a corporate subscription simply register your email address here to gain access